Oligomerix
Patricia Lopez has worked in the laboratory field for over 15 years. Patricia began their career in 2003 as a Research Technician and Student Intern at Q-RNA, Inc. Patricia then moved to Columbia University Medical Center in 2006, where they held the positions of Staff Associate - Lab Manager and Senior Technician. In 2010, they joined Oligomerix, Inc. as Lab Manager and Senior Research Associate.
Patricia Lopez obtained their Master of Arts (M.A.) in Biotechnology from Columbia University in 2008, and their Bachelor of Arts (B.A.) in Biology, General from Hunter College.
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.